MedTrace Logo

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

NCT00003747 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and temozolomide in treating patients who have unresectable or metastatic melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

carboplatin

DRUG

temozolomide

Sponsors & Collaborators

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    lead OTHER

Principal Investigators

  • Gordon J.S. Rustin, MD · Mount Vernon Cancer Centre at Mount Vernon Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003747 on ClinicalTrials.gov